MK-677 (Ibutamoren): Research, Purity and Sourcing

The most misunderstood fact about MK-677 sits in plain sight: it isn't a peptide. Ibutamoren is a non-peptide spiropiperidine small molecule that binds the same receptor ghrelin binds, and that receptor overlap is the only reason MK-677 ends up catalogued beside peptide secretagogues like CJC-1295 and ipamorelin. Same target. Completely different molecule class, stability profile and analytical workflow.

Our team has answered the same three questions about MK-677 from laboratory buyers for years: what the receptor actually does, how long the compound persists, and how to confirm a vial matches its label. This page is built around those three. Every study claim links to its PubMed record, and where the literature is genuinely thin, we say so rather than filling the gap with confident-sounding filler.

What is MK-677?

MK-677 (ibutamoren, originally coded MK-0677) is an orally active, non-peptide growth hormone secretagogue that activates the ghrelin receptor GHS-R1a, amplifying pulsatile growth hormone release and raising circulating IGF-1 across published animal and human studies. It has never been approved as a medicine in any jurisdiction. MK-677 is supplied strictly as a laboratory research chemical.

The oversimplification worth killing early: MK-677 does not supply growth hormone and does not behave like recombinant GH. It acts upstream at a receptor, so the size of the downstream response depends entirely on whether the pituitary somatotrophs in a given model can still respond. That single distinction explains most of the contradictory claims circulating online. What follows covers the receptor mechanism, the actual published record by species, the adverse findings on file, reported pharmacokinetics and half-life, how a vial is verified by HPLC and mass spectrometry, laboratory handling, regulatory status, and how it sits against related compounds.

What exactly is ibutamoren, chemically?

MK-677 is a non-peptide spiropiperidine growth hormone secretagogue, commonly supplied as the mesylate salt. The chemistry matters more than catalogue placement suggests. Ipamorelin and CJC-1295 are amino-acid chains joined by peptide bonds, which leaves them vulnerable to peptidase cleavage and generally unsuitable for anything other than parenteral research models. MK-677 contains no peptide bonds. A 1998 report in the Journal of Clinical Endocrinology and Metabolism describes it specifically as an orally active secretagogue (PubMed 9467534), and that property is a direct consequence of its small-molecule structure.

So when a search reads 'MK-677 peptide', it describes a shelf category rather than a molecular class. Three practical consequences follow for any lab. Identity is confirmed against a small-molecule reference standard by mass spectrometry, not by amino-acid sequencing. Degradation risk runs through oxidation, moisture and light exposure rather than enzymatic cleavage. And the handling tolerances differ meaningfully from a lyophilised peptide, which is why storage advice copied from a peptide protocol sheet often misses the real failure modes.

In our experience, the peptide-versus-small-molecule confusion is the single most common misunderstanding we correct for new research accounts. It is not pedantry. It changes which certificate tests actually prove identity, and it changes what a sloppy supplier can get away with. Labs sourcing research-grade ibutamoren or planning concentrated solution work should start from the chemistry, not the category label.

How does the ghrelin receptor become a growth hormone signal?

MK-677 is an agonist at GHS-R1a, the growth hormone secretagogue receptor that endogenous ghrelin activates. GHS-R1a is a Gq/11-coupled G protein-coupled receptor: agonist binding activates phospholipase C, which generates inositol trisphosphate, which releases intracellular calcium stores inside pituitary somatotrophs and triggers growth hormone exocytosis. There is a second arm in the hypothalamus, where secretagogue signalling reduces somatostatin tone (the brake on GH release) while amplifying GHRH pulses (the accelerator).

The net published pattern is an increase in GH pulse amplitude rather than a flat, continuous elevation, with hepatic IGF-1 rising downstream over following days. A 1997 review in the European Journal of Endocrinology laid out this architecture for the growth hormone-releasing peptide class before the non-peptide secretagogues matured (PubMed 9186261).

Here is the part most summaries skip. GHS-R1a is also expressed on NPY and AgRP neurons in the arcuate nucleus, which means appetite signalling is not a side effect of a GH drug. It is the same receptor doing its other native job. Any model built to study the GH axis with MK-677 is simultaneously running an orexigenic intervention, and the two effects cannot be cleanly separated by study design alone. That overlap is why appetite-focused research questions and GH-axis questions keep colliding, and why the secretagogue mechanics that strength-sport readers ask about rarely map onto what the pituitary data actually show.

What has actually been studied, and in which species?

The MK-677 evidence base is broader than sceptics assume and considerably thinner than marketing implies. The 1998 Journal of Clinical Endocrinology and Metabolism study reported that this orally active secretagogue reversed diet-induced catabolism in a human research setting (PubMed 9467534). The largest clinical investigation on record is a multicentre, randomised, placebo-controlled phase IIb trial in patients recovering from hip fracture (PubMed 21067829). The compound never progressed to approval anywhere, which is itself a data point worth sitting with.

Animal work fills in the mechanism. Repeat exposure in beagles increased and maintained elevated IGF-I (PubMed 9071975), establishing that the secretagogue response does not simply exhaust itself. In an Alzheimer's model, MK-0677 alleviated amyloid beta-related pathology in 5XFAD mice (PubMed 29912176), which is why ghrelin agonism keeps resurfacing in neurodegeneration literature.

Now the finding almost nobody quotes. A 1999 study in Hormone and Metabolic Research reported that IGF-1 and growth hormone levels in canine cerebrospinal fluid were unaffected by GH or MK-0677 exposure (PubMed 10226793). Peripheral IGF-1 can move while the central compartment stays flat. Any inference that a rising serum IGF-1 reading means a correspondingly altered central environment is an assumption that one dataset directly contradicts. We flag this constantly when reviewing study designs, because it is the difference between measuring a biomarker and measuring a mechanism. Research questions around bone density endpoints, sleep architecture and recovery models all inherit this compartment problem.

What adverse findings and open questions appear in the literature?

The single most concrete adverse report on file is a 2025 BMJ Case Reports paper describing hepatotoxicity induced by MK-677 (PubMed 40675653). One published case is a signal, not an incidence rate, and it should be read as exactly that. It does not establish frequency. It does establish that hepatic injury has been attributed to this compound in the peer-reviewed record.

Beyond that, the honest position is that the class-level concerns come from GH-axis physiology rather than from a large MK-677 safety dataset, because no such dataset exists. Sustained IGF-1 elevation is associated in endocrine literature with reduced insulin sensitivity and higher fasting glucose, and fluid retention, peripheral oedema and joint discomfort are recurrent findings across growth hormone research generally. Researchers also raise IGF-1 signalling and proliferative risk as a theoretical question, which is a hypothesis in the literature rather than a demonstrated outcome for this compound. A 2026 review in the American Journal of Sports Medicine situates compounds in this category within the wider peptide supplement landscape (PubMed 42578445).

The unknowns deserve equal billing. There is no long-term human safety follow-up, no approved labelling, and no regulatory pharmacovigilance stream collecting adverse events, which means absence of reports is not evidence of absence of harm. Questions around glucose handling and proliferative risk remain genuinely open in the literature, and anyone claiming otherwise is selling something.

How long does MK-677 stay active? Half-life and detection windows

Published pharmacology describes MK-677 as orally active with an elimination half-life commonly reported in the range of roughly four to six hours. That number answers one question only: how fast the parent compound leaves plasma. It does not describe how long the biological signal persists, and it does not describe how long an analytical laboratory can still find evidence of exposure. Three different clocks, routinely conflated.

The pharmacodynamic clock runs longer than the pharmacokinetic one. IGF-1 does not circulate free. It travels in a ternary complex bound to IGFBP-3 and the acid-labile subunit, which extends IGF-1's own half-life well beyond that of the compound that triggered its release. This is the mechanistic reason a short-lived secretagogue can produce a biomarker shift that persists across days, and why study designs sampling at a single timepoint can mislead badly.

The analytical clock runs longest of all. Equine doping-control research has mapped MK-0677 metabolism in vitro and in urine and plasma (PubMed 35302297), characterised its possible metabolites in thoroughbreds by mass spectrometry (PubMed 35716382), and demonstrated detection in equine hair (PubMed 36354265). A 2026 Clinica Chimica Acta paper used ibutamoren as its worked example for interpreting hair-test results against minimal detectable quantities (PubMed 40882886). Keratinised matrices retain evidence long after plasma is clear. Questions about circadian timing in the record, repeat-exposure models and oral bioavailability all trace back to these three clocks.

How do laboratories verify a vial matches its label?

Verification rests on two separate questions that a single percentage cannot answer. Purity asks how much of the material is the main component. Identity asks whether that main component is actually ibutamoren. A certificate of analysis that reports one without the other proves very little.

HPLC (high-performance liquid chromatography) separates components by their interaction with a stationary phase and reports purity as area percent across the chromatogram, with 98 percent and above being the common benchmark for research-grade material. Mass spectrometry answers identity by measuring mass-to-charge ratios against the expected molecular signature, and it is the same technique the equine doping-control papers above relied on to confirm the compound and its metabolites. A complete certificate names the testing laboratory, carries a lot number that matches the vial physically in hand, shows the test date, and includes the raw chromatogram rather than a summary figure typed into a template.

Three failure patterns show up repeatedly in certificates we are asked to review. A purity figure with no accompanying mass spectrum. A lot number that appears nowhere on the container. And a document described as third-party with no independent laboratory named anywhere on it. Real Peptides supplies MK-677 for laboratory research with a published certificate of analysis, viewable in our COA library. Researchers comparing third-party tested supply, research-grade sourcing standards or online purchasing criteria should treat the certificate as the product specification, not as marketing collateral.

How is ibutamoren handled and stored in a laboratory?

Solid material belongs somewhere cool, dark, dry and sealed, ideally desiccated, with many laboratories holding long-term solid stocks at minus 20 degrees Celsius. Prepared solutions are generally held refrigerated at 2 to 8 degrees Celsius, protected from light, and treated as having a finite working life from the day they are made rather than from the day the vial arrived.

Because MK-677 is a small molecule rather than a peptide chain, the dominant degradation risks are oxidation, hydrolysis from ambient moisture and photodegradation, not enzymatic breakdown. That distinction cuts both ways. The material is more forgiving of brief ambient excursions than a reconstituted peptide would be, and simultaneously easier to quietly damage through repeated freeze-thaw cycling or storage in a clear container on a bright bench. Neither failure announces itself visually.

Labelling discipline is the unglamorous part that prevents most of the real problems. Every container should carry compound name, lot number, solvent, preparation date and preparer initials, because an unlabelled vial in a shared refrigerator is an unusable vial regardless of how pure it started. Our team has seen more research material written off through ambiguous labelling than through genuine chemical degradation. Laboratories formalising their solution-preparation workflow should also review the common preparation errors that compromise concentration accuracy before any measurement is taken.

Is MK-677 legal to buy, and under what status?

MK-677 is not an approved medicine in any jurisdiction and is not a lawful dietary supplement ingredient. United States regulators have acted against products marketing growth hormone secretagogues as supplements, and the World Anti-Doping Agency prohibits growth hormone secretagogues under its S2 category at all times, in and out of competition, which is precisely why so much of the modern analytical literature on this compound comes from doping-control laboratories rather than clinical ones.

All compounds discussed on this page are sold for research use only and are not for human consumption.

Legal status for purchase varies by jurisdiction, and import rules differ considerably between countries even where domestic research supply is permitted. Institutional buyers should verify local requirements before ordering, and our service coverage information outlines where we ship. A substantial share of the most rigorous ibutamoren data comes from veterinary and equine science, so it is worth stating plainly: nothing here is veterinary guidance, and anyone with a question about an animal's health should take it to their veterinarian. Researchers in sport-adjacent fields should read the anti-doping context alongside sourcing diligence practices before procurement.

How does it compare with CJC-1295 and ipamorelin?

All three compounds raise growth hormone output, and all three do it through different molecular routes with very different evidence depth behind them. The table below compares what each molecule is, where it binds, and how much published human research actually exists.

The comparison most researchers actually want is mechanism against evidence depth, which is covered in detail in our breakdown of mechanism and real differences, the three-way receptor comparison, and the questions raised by combined-compound study designs.

What If: common laboratory scenarios

What if the certificate of analysis has no lot number?

Treat the certificate as unlinked to the vial and request the lot-specific document before the material enters any experiment. A certificate without a matching lot number demonstrates that a supplier tested something at some point, which is not the same as demonstrating what is inside the container on your bench. Lot traceability is the entire mechanism by which a quality problem can later be isolated rather than contaminating every dataset produced in that period.

What if a shipment arrived warm?

Quarantine the material, document the arrival condition with photographs and timestamps, and contact the supplier before opening anything. Solid MK-677 is considerably more tolerant of brief ambient excursions than a reconstituted peptide, because its failure modes are oxidation and moisture rather than enzymatic degradation, but tolerance is not immunity and visual inspection cannot confirm integrity. Documentation at the point of receipt is what makes a replacement conversation straightforward instead of contested.

What if a prepared solution looks cloudy or shows particulates?

Stop and discard rather than filtering and proceeding. Cloudiness or visible particulate matter in a solution that was previously clear indicates either precipitation from solubility limits, microbial contamination, or a solvent incompatibility, and all three invalidate concentration assumptions downstream. Filtering removes the visual symptom while leaving the underlying analytical uncertainty entirely intact, which is the worst of both outcomes.

What if two studies report contradictory IGF-1 findings?

Check the compartment and the sampling timepoint before assuming either result is wrong. Serum and cerebrospinal fluid behave as separate compartments in the published canine data, and the ternary-complex binding of IGF-1 means a single timepoint can land anywhere on a multi-day curve. Most apparent contradictions in the MK-677 literature resolve into differences in what was measured, where, and when.

The blunt truth about secretagogue marketing

Here's the honest answer: almost everything written about MK-677 online describes outcomes the published literature has not established. The record contains one phase IIb trial that never led to approval, a scatter of animal studies, a published hepatotoxicity case, and a large and growing body of doping-control analytical work whose entire purpose is detecting the compound rather than endorsing it. That is a legitimate research subject. It is not a validated intervention, and any source presenting it as one is working from marketing copy rather than from PubMed. Compare the reported side effect and mechanism differences across the class and the gap becomes obvious fast.

How we researched this page

Every study claim on this page is drawn from peer-reviewed literature indexed in PubMed and linked inline to its record, so each citation can be checked at source rather than taken on trust. We did not conduct first-party testing for this article and we make no claims based on internal experiments. Where the literature reports a single case rather than a rate, we say so. Where a figure such as the half-life range is commonly cited but not uniformly reported across sources, it is presented as an approximate range rather than a precise value. Mechanistic descriptions of GHS-R1a signalling reflect established receptor pharmacology for the growth hormone secretagogue class as summarised in the reviews cited above.

Researchers working through the wider MK-677 question set may find the adjacent material useful: the growth hormone tool comparison, the head-to-head CJC-1295 analysis, research-grade ibutamoren sourcing for laboratories, and our shipping terms for research accounts.

MK-677 occupies an unusual position in the research chemical landscape: a compound with more rigorous published science behind it than most of its shelf neighbours, and simultaneously more unanswered safety questions than its online reputation admits. The analytical literature of the last four years tells the real story. The most sophisticated recent work on this molecule was not funded to find out whether it helps anyone. It was funded to find out how long it can be detected in hair. When the sharpest science on a compound comes from laboratories trying to catch it rather than laboratories trying to validate it, that context belongs in every assessment of what the evidence actually supports.

References

Peer-reviewed sources on MK-677 (Ibutamoren) indexed in PubMed, listed for research context. Real Peptides supplies MK-677 (Ibutamoren) for laboratory research use only.

1. Hepatotoxicity induced by MK-677. BMJ case reports, 2025. PMID 40675653. doi:10.1136/bcr-2025-265728
2. LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report. Experimental physiology, 2022. PMID 36303408. doi:10.1113/EP090741
3. Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats. Yonsei medical journal, 2018. PMID 30450851. doi:10.3349/ymj.2018.59.10.1174
4. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology, 2008. PMID 19015485. doi:10.1212/01.wnl.0000335163.88054.e7
5. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. The Journal of clinical endocrinology and metabolism, 1998. PMID 9467534. doi:10.1210/jcem.83.2.4551
6. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology, 1997. PMID 9349662. doi:10.1159/000127249
7. Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proceedings of the National Academy of Sciences of the United States of America, 1995. PMID 7624358. doi:10.1073/pnas.92.15.7001